about the fund

Amunix is a platform company developing technology for tumor-specific activation of T-cell engagers.

Ankyra is developing a platform to significantly improve both the safety and efficacy of cytokine immunotherapies for cancer.

BeMe Health is a digital mental health company focused on the support and treatment of teens and adolescents struggling with mental illness.

ByHeart is a fully integrated infant nutrition company dedicated to translating leading nutrition science and breastmilk research into products that set the best foundation for babies’ health.

Candesant is dedicated to developing novel solutions for excessive sweating and hyperhidrosis

Delphia is pioneering activation lethality – a next-generation precision medicine approach targeting cancer’s vulnerability to oncogene overactivation.

Dewpoint is translating new insights into biomolecular condensates and cellular function to uncover treatments for the toughest disease.

Engine Biosciences is a Singapore-based drug discovery company using a proprietary AI and CRISPR-based platform to identify novel precision oncology targets.

Folx Health is a digital health and wellness platform that delivers personalized, consumer grade, Queer-competent health care, centered on the LGBTQIA community.

Glympse Bio is transforming disease monitoring with a novel class of highly tunable and bioengineered activity sensors that query the body for disease status and report out clinically relevant insights rapidly and noninvasively.

Hummingbird focuses on engineering and developing next-generation therapies against important biologically validated targets in cancer and autoimmune disease which have been elusive and difficult to drug.

IconOvir engages in research and development in cancer viral gene therapy.

Kallyope is developing an industry-leading platform to harness the gut-brain axis.

KenSci is a healthcare data science company that uses machine learning to provide operational and clinical insights for hospital and health systems.

Kronos Bio is dedicated to the discovery and development of novel small molecule modulators of historically undruggable oncology targets.

Montis Biosciences is targeting perivascular macrophages to restore tumor micro environment vasculature- increase immune infiltration and alleviate the immune suppressive TME.

Muna Therapeutics is a neurology focused biotech company working on developing novel therapeutics for neurodegenerative diseases.

Nomad Health is a workforce marketplace that facilitates the hiring of physicians and nurses on behalf of healthcare provider organizations.

The One Health Company, maker of FidoCure®, is bringing the latest advances in human oncology – individualized, precision medicine – to dogs with cancer.

QurAlis is developing precision therapies for the treatment of ALS.

Satellite Bio has pioneered a novel type of regenerative medicine, Adaptive Tissue Therapeutics, to target a range of elusive, life-threatening diseases.

Sesh Therapy offers online support group sessions facilitated by a trained therapist.

SunBird Bio is developing protein-based diagnostic tests that provide unprecedented insights to enable earlier, more accurate diagnosis and treatment of Alzheimer’s disease, other neurological disorders and early-stage cancer. Through its merger with Glympse Bio, SunBird Bio brings two leaders in the protein diagnostics field together to focus on platform development and improve patients outcomes.

Suono Bio, Inc. enables ultrasonic targeted delivery of therapeutics and macromolecules across tissues without the need for reformulation or encapsulation. Preclinical studies have demonstrated the capacity to deliver small molecules, proteins, vaccines, and nucleic acids locally to specific tissues such as the gastrointestinal tract, as well as systemically in a formulation-independent manner.

Thirty Madison is an end-to-end digital health platform that connects patients directly to provider specialists.

Vico Therapeutics is developing therapies for rare neurological diseases, leveraging RNA modifying technologies.

Volastra is developing novel therapeutics to tackle hard to treat cancers by harnessing unique insights into the mechanisms by which Chromosomal Instability impact and drive cancer cells.

Oui is developing an app to help manage mental health.

Capstan Therapeutics is developing a targeted delivery platform and therapeutics to reprogram immune cells in vivo for a broad range of disease categories.

EpiBiologics is a next generation targeted protein degradation company developing antibody-based therapeutics that degrade extracellular or transmembrane targets.

65LAB serves as a biotech company incubator which identifies, funds and supports the formation of new companies sourced from academic and research institutions in Singapore.

Larkspur Biosciences is developing precision immunotherapies targeting the key intersection between the tumor and the immune system.

Triveni Bio is a biotechnology company focused on providing a genetics-informed precision medicine approach for I&I disorders. The company is the result of a merger between Amagma Therapeutics, a Polaris portfolio company, and Modify Therapeutics.

UpDoc is a tech-enabled services company providing the first-ever proprietary conversational AI platform for medication management.